Evidence map›Paper›PMID 41559517›Full record

ArticleACS infectious diseases2026

Protective Effects of rLPG3 Plus Freund's Incomplete Adjuvant on Parasitism, Hepatic Function, and Immune Modulation in Experimental Visceral Leishmaniasis.

Daniel Silva Sena Bastos, Bianca Meirelles Miranda, Caroline Itagiba Rooke, Neverton José Silva Ferreira, Luiz Otávio Guimarães Ervilha, Renner Philipe Rodrigues Carvalho, Ana Cláudia Ferreira Souza, Mariana Machado Neves, Leandro Licursi de Oliveira, Eduardo de Almeida Marques da Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel Silva Sena BastosLaboratory of Immunoparasitology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Bianca Meirelles MirandaLaboratory of Immunoparasitology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Caroline Itagiba RookeLaboratory of Immunoparasitology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Neverton José Silva FerreiraLaboratory of Immunoparasitology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.ORCID 0000-0003-1902-6529
Luiz Otávio Guimarães ErvilhaLaboratory of Structural Biology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Renner Philipe Rodrigues CarvalhoLaboratory of Structural Biology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Ana Cláudia Ferreira SouzaLaboratory of Structural Biology, Department of Animal Biology, Federal Rural University of Rio de Janeiro, Seropédica, Rio de Janeiro, 23890-000, Brazil.
Mariana Machado NevesLaboratory of Structural Biology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Leandro Licursi de OliveiraLaboratory of Immunochemistry and Glycobiology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.
Eduardo de Almeida Marques da SilvaLaboratory of Immunoparasitology, Department of General Biology, Federal University of Viçosa, Viçosa, Minas Gerais, MG, 36570-000, Brazil.ORCID 0000-0003-4015-5915

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Visceral leishmaniasis (VL) is a neglected tropical disease affecting humans and dogs, particularly in urban settings. Current therapies are limited by toxicity, lengthy regimens, and emerging drug resistance. No human vaccine is available, and only a few licensed formulations exist for canine use. Here, we evaluated a recombinant Leishmania infantum lipophosphoglycan-3 (rLPG3) antigen formulated with Freund's incomplete adjuvant (FIA) against

Indexed as

Antigens, ProtozoanFreund's AdjuvantLeishmania infantumLeishmaniasis VaccinesLeishmaniasis, VisceralLiverAdjuvants, ImmunologicAnimalsAntibodies, ProtozoanDisease Models, AnimalFemaleImmunoglobulin GLipidsMiceMice, Inbred BALB CProtein Subunit VaccinesAdjuvants, ImmunologicAntibodies, ProtozoanAntigens, ProtozoanFreund's AdjuvantImmunoglobulin Gincomplete Freund's adjuvantLeishmaniasis VaccinesLipidsProtein Subunit VaccinesHepatoprotectionLPG3Oxidative StressVaccineVisceral leishmaniasis

Identifiers

PMID41559517
PMCPMC12910578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.